Articles
11.11.2026
 JCA as a governance challenge: Aligning global, ...

Given the overlap in Joint Clinical Assessment (JCA) and national-level HTA timelines, manufacturers...

Read more
Articles
02.11.2026
JCA Evidence Gaps: Meeting National Payer Needs

Introduction The EU Joint Clinical Assessment (JCA) was introduced to reduce duplication and establi...

Read more
Articles
22.10.2026
From JCA convergence to national divergence: Diagn...

Joint Clinical Assessment (JCA) provides a common EU-level clinical assessment, but national HTA and...

Read more
Articles
05.10.2026
Forecasting PICOs early: What if your final eviden...

Manufacturers should not wait for final HTA scopes to test whether their evidence package can addres...

Read more
Articles
21.09.2026
From Global Price Ambition to Local Access Reality...

Pricing research is often treated as a launch-stage exercise focused on testing a target price. But ...

Read more
Articles
09.09.2026
Choosing payer pricing research? Start with the qu...

Different budget pressures create different payer pricing challenges  Healthcare budget pressur...

Read more
Articles
10.08.2026
The Hidden Risk in Pharma Pricing: When Poor Gover...

Pricing strategies rarely fail because of one decision. More often, price potential is gradually ero...

Read more
Articles
22.07.2026
Defending Price Under HTA Scrutiny: Why Evidence M...

Price ambition is only defensible when the evidence can carry it  Manufacturers can no longer r...

Read more
Articles
06.07.2026
Why Pricing Strategy Must Start Earlier: Linking E...

Pricing strategy is often treated as a launch activity. However, by the time teams begin detailed pr...

Read more
Articles
22.06.2026
Mid-Year Trends Refresh of 2026 Predicted Pharma P...

At the start of 2026, we identified five key pharmaceutical pricing and market access trends expecte...

Read more

Stay in the know, subscribe to our newsletter

Be the first to receive exclusive content on the latest from the pharmaceutical and market access sector.